Adiponectin Receptor Agonist Improves Muscle Measures in Rat Studies

A small molecule that mimics adiponectin signaling promoted muscle growth and improved several measures of muscle function in cell experiments and rat models, according to research reported by Fight Aging! The compound, called Med, is the water-soluble sodium salt of medicarpin, a previously described osteogenic phytoalexin.

The study focused on adiponectin receptors AdipoR1 and AdipoR2, which are involved in skeletal muscle metabolism, regeneration and oxidative capacity. Because adiponectin itself is a large, structurally complex molecule, the researchers investigated whether a smaller compound could activate the same signaling pathway.

In laboratory cell experiments, Med enhanced myogenic differentiation—the process by which muscle cells develop and form muscle fibers. Treated cells produced more myotubes and showed increased expression of the muscle-related markers MyoD, myogenin and MyHC. The compound also increased fatty acid oxidation and elevated markers associated with oxidative muscle fibers, findings the researchers interpreted as evidence of enhanced oxidative capacity.

The researchers then tested oral Med administration in two rat models of skeletal muscle atrophy. The treatment was reported to lessen muscle loss, with improvements in muscle morphology, lower activity of atrogenes—genes associated with muscle wasting—and increases in myogenic markers. The rats also showed greater muscle adiponectin expression and corresponding downstream signaling.

Functional testing produced improvements across several measures. Med-treated rats performed better in grip-strength and wire-hanging tests, as well as on a rotarod assessment. The researchers also reported improved toe-spread ability in limbs affected by denervation.

The findings are relevant to research into muscle atrophy associated with aging and chronic disease, for which the source describes effective pharmacotherapies as still unavailable. They also place Med among small-molecule approaches intended to influence muscle metabolism rather than relying on adiponectin itself.

However, the reported evidence is limited to in vitro experiments and rodents. The study does not establish that Med promotes muscle growth, prevents atrophy or improves physical performance in humans. It also does not provide evidence of human safety, dosing, regulatory status or clinical effectiveness. The work was reported in the context of research published on September 2, 2026, with the study linked through the Journal of Cachexia, Sarcopenia and Muscle.